Pacemaker Longevity & Lead Reliability Patent Landscape
This field is tightly concentrated, with Medtronic and Pacesetter together accounting for the large majority of ranked filings and the United States serving as the dominant filing jurisdiction. Annual volume peaked in 2020 and has eased since, signalling a field entering decline rather than active expansion.
Medtronic leads a highly consolidated field
Medtronic is the clear front-runner in pacemaker longevity and lead reliability patents, holding the top position in the applicant ranking by a substantial margin over second-placed Pacesetter. The top five filers account for 77% of the combined output of the hundred largest filers, indicating an unusually concentrated competitive structure.
There is a pronounced tier gap between Medtronic and Pacesetter at the top and the remaining applicants. Biotronik SE & Co KG holds third place with a noticeably smaller share, and the fourth- and fifth-ranked applicants — Advanced Neuromodulation Systems and Cardiac Pacemakers — are significantly smaller still. Beyond the top five, the field fragments into single-digit or single-record filers, many of them individual inventors or small institutions.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | Medtronic | 82 | |
| 2 | Pacesetter Inc | 44 | |
| 3 | BIOTRONIK SE & CO KG | 11 | |
| 4 | Advanced Neuromodulation Systems Inc | 6 | |
| 5 | Cardiac Pacemakers Inc | 4 | |
| 6 | PiezoCap Inc | 3 | |
| 7 | Micardia Corp | 3 | |
| 8 | Nimon Yevgeniy S | 2 | |
| 9 | Gadson Gregory P (MS 301) | 2 | |
| 10 | PolyPlus Battery Co Inc | 2 |
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 11 | Katz Bruce D | 2 | |
| 12 | Shockwave Medical Inc | 2 | |
| 13 | Visco Steven J | 2 | |
| 14 | Onward Medical NV | 2 | |
| 15 | GLA University Mathura | 1 | |
| 16 | Gadson Gregory P | 1 | |
| 17 | Ms U Vanitha | 1 | |
| 18 | Mr N Girinath | 1 | |
| 19 | Dr J R Dinesh Kumar | 1 | |
| 20 | Dr Pawan Singh | 1 |
Medtronic’s dominant position implies strong freedom-to-operate constraints for new entrants targeting the core electrotherapy space (A61N). Any challenger seeking to operate in the mainstream of this field must either design around Medtronic’s portfolio or establish a differentiated position in adjacent branches where coverage is sparse.
The most recent 18–24 months of filing data are subject to publication lag and likely under-represent actual activity; the apparent low counts for 2024–2026 should not be read as confirmation of the decline trend alone. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
Post-peak activity and a narrow technology base
Annual filing volume and technology class composition together reveal a field that built rapidly to a 2020 peak and has since eased, while remaining anchored almost entirely in a single IPC branch. These two charts provide the context for assessing where incremental R&D investment is likely to encounter saturation versus open territory.
Annual filing trend
Filings grew from 3 records in 2017 to a peak of 18 in 2020, then fell sharply before a partial recovery in 2023. The post-2023 readings (2024–2026) are affected by publication lag and should be treated as provisional. The overall trajectory is consistent with a field that expanded rapidly, reached saturation around 2020, and is now in a declining phase.
↗ Hover for values · click a bar to ask EurekaTechnology composition
A61N (Electrotherapy & radiation therapy) dominates the technology mix by a wide margin, reflecting the core implantable stimulation focus of this corpus. A61B (Diagnosis & surgery) is the only secondary branch with meaningful presence; all other IPC classes — including G16H (Healthcare informatics), H02J (Power supply), and H05K (Printed circuits) — each account for a small fraction of total records, confirming the field’s narrow technological scope.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Cardiac pacemaker with programmable output pulse a…
An implantable cardiac pacemaker having programmable stimulating pulse amplitudes selectable by means of an external programming unit. The pacemaker includes charge pump circuitry for developing a stimulating pulse voltage on an output capacitor. The output capacitor is charged to a selected level identified by a multiple-bit amplitude value communicated to… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Catheter, cardiac pacemaker and method of pacing | 406 |
| 2 | Rate responsive pacemaker and methods for optimizi… | 390 |
| 3 | Method and apparatus for monitoring pacemaker inte… | 272 |
| 4 | Pacemaker implant recognition | 250 |
| 5 | Method and apparatus for rate-responsive cardiac p… | 223 |
| 6 | Method and apparatus for automatic pacing threshol… | 212 |
| 7 | Implantable cardiac stimulation device having a pr… | 200 |
| 8 | Low energy pacing pulse waveform for implantable p… | 192 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
What the patent structure means for R&D investment decisions
Three structural features — life-cycle stage, extreme concentration, and sparse adjacent branches — define the strategic context. Each has direct implications for where new R&D capital is likely to generate differentiated IP.
Field in decline from a 2020 peak
The lifecycle evidence places this field in a decline stage. Annual filings peaked in 2020 at 18 records and have eased back since, with the multi-year window showing a 33% contraction. R&D teams entering this space now are competing against an entrenched incumbent portfolio rather than riding an open wave of uncharted territory.
Lifecycle: DeclineTop five filers hold 77% of ranked output
The top five applicants — Medtronic, Pacesetter, Biotronik, Advanced Neuromodulation Systems, and Cardiac Pacemakers — collectively account for 77% of the combined output of the hundred largest filers. This level of concentration leaves limited room for new entrants to establish broad coverage in the core A61N space without directly challenging well-resourced incumbents. Niche differentiation in adjacent branches is the more accessible path.
High concentrationNo co-applicant activity detected
The collaboration evidence shows no co-filing relationships in this corpus. The absence of joint applicants suggests that pacemaker longevity and lead reliability innovation has been pursued as proprietary, in-house R&D by the major players rather than through open consortia or academic partnerships. This may reflect the regulated, liability-sensitive nature of implantable device IP.
No co-filing detectedUnited States is the dominant filing jurisdiction
The United States leads all jurisdictions by a wide margin, followed by the EPO and WIPO (PCT). Australia and Canada are secondary markets with modest coverage, while India records a small number of filings. The strong US-EPO-PCT concentration reflects where the primary commercial markets and regulatory pathways sit, and also where freedom-to-operate searches must be most thorough.
US-centricGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
Co-filing pairs, ranked by the number of jointly-filed patent families.
Medtronic and Pacesetter dominate; Biotronik is the rising challenger
Two legacy device makers hold the top two positions by a wide margin, while Biotronik has entered the recent period as a new filer in this specific corpus. Technology emphasis across all top players converges on A61N1, with only minor differentiation in secondary branches.
Medtronic
Medtronic holds the top position with 82 patent records, concentrated almost entirely in A61N 1 (Electrotherapy & radiation therapy), with secondary coverage in A61B 5 (Diagnosis & surgery) and G01R 31 (Electric & magnetic measurement). Its momentum trend is recorded as a new entrant in the recent period, which from this size of base likely reflects renewed filing activity in this specific sub-corpus rather than a genuinely new presence in cardiac devices.
patent records: 82Biotronik SE & Co KG
Biotronik holds third place with 11 patent records, focused on A61N 1 and A61B 5. Its momentum is recorded as a new entrant in the recent period, suggesting this activity represents a new or renewed push into the pacemaker longevity and lead reliability sub-space. Pacesetter, the second-ranked filer with 44 patent records, shows a contrasting trend of minus 77%, indicating a sharp pullback from earlier activity.
patent records: 11| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| Medtronic | 4 | ▲ new entrant |
| Pacesetter Inc | 5 | ▼ -77% |
| Biotronik SE & Co KG | 11 | ▲ new entrant |
| Advanced Neuromodulation Systems Inc | 2 | ▲ new entrant |
| PiezoCap Inc | 3 | ▲ new entrant |
Under-served adjacent branches worth monitoring
Several IPC branches appear in the corpus with very low record counts relative to the dominant A61N class. These represent areas of relative sparsity adjacent to the core technology; they are observations of current coverage gaps, and should only be pursued where technical relevance and a realistic entry path can be confirmed.
H02J · Power supply & grid systems
H02J records only 4 patent records in this corpus, representing roughly 2% of IPC-tagged records. For a technology whose longevity is directly gated by energy management — battery depletion is the primary reason leads and devices are replaced — the scarcity of power supply IP is a notable observation. Entrants with expertise in low-power circuit design or energy harvesting for implantables could find this branch comparatively open, provided they can navigate the dominant A61N incumbents on the system level.
Search this in Eureka →H05K · Printed circuits & assemblies
H05K also shows only 4 patent records, suggesting that the substrate and assembly layer of pacemaker leads — including flexible or miniaturised PCB approaches relevant to chronic implant reliability — is under-patented in this corpus. Given the industry trend toward smaller, leadless, and more mechanically robust devices, miniaturised assembly techniques represent a plausible technical adjacency. Pacesetter is the only top-ranked applicant with H05K coverage, leaving the branch relatively open to new claimants.
Search this in Eureka →Frequently asked questions
The corpus covers 92 patent families in the pacemaker longevity and lead reliability space across a global scope.
Medtronic is the leading assignee with 82 patent records, placing it well ahead of the second-ranked filer, Pacesetter, which holds 44 patent records.
The evidence places this field in a decline stage. Annual filings peaked in 2020 and have eased back, with the multi-year window showing a 33% contraction in recent growth.
The United States is the primary jurisdiction, followed by Europe (EPO) and WIPO (PCT). Australia and Canada are secondary markets. Any freedom-to-operate analysis should prioritise the US and EPO in particular.
No co-applicant relationships are detected in this corpus. Innovation in pacemaker longevity and lead reliability appears to have been pursued as proprietary, in-house R&D by the major incumbent players.
G16H (Healthcare informatics), A61M (Devices for body fluids), G01R (Electric & magnetic measurement), H02J (Power supply & grid systems), and H05K (Printed circuits & assemblies) each account for only 4–5 patent records in the corpus, making them the sparsest adjacent branches relative to the dominant A61N class.
Built on Patsnap Open Platform
This report’s underlying patent dataset — filings, assignees, technology clusters — is open for developers via MCP and REST API. Free to start, 10,000 credits, no credit card required.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.